NCT00413725View on ClinicalTrials.gov

Safety and Efficacy of a Three-Dose Regimen of an Adenoviral HIV Vaccine (MRKAd5 HIV-1 Gag/Pol/Nef) in HIV Uninfected South African Adults

PHASE2CompletedINTERVENTIONAL
Enrollment

801

Participants

Timeline

Start Date

January 31, 2007

Primary Completion Date

August 31, 2012

Study Completion Date

August 31, 2012

Conditions
HIV Infections
Interventions
BIOLOGICAL

MRKAd5 HIV-1 gag/pol/nef

Experimental Clade-B based Adenovirus serotype 5 HIV-1 gag/pol/nef vaccine

OTHER

Placebo

Placebo

Trial Locations (5)

1862

Soweto HVTN CRS, Johannesburg

2571

CAPRISA Aurum CRS, Klerksdorp

4001

eThekwini CRS, Durban

7750

Emavundleni CRS, Cape Town

0204

MedCRU CRS, Pretoria

All Listed Sponsors
collaborator

HIV Vaccine Trials Network

NETWORK

lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT00413725 - Safety and Efficacy of a Three-Dose Regimen of an Adenoviral HIV Vaccine (MRKAd5 HIV-1 Gag/Pol/Nef) in HIV Uninfected South African Adults | Biotech Hunter | Biotech Hunter